BEATRICE

NCT00528567 📎

Regimen

Experimental
Bevacizumab 5 mg/kg/week equivalent (10 mg/kg Q2W or 15 mg/kg Q3W) IV for 1 year alongside/after adjuvant chemotherapy.
Control
Observation after completing chemotherapy (no bevacizumab).

Population

Operable triple-negative invasive breast cancer after surgery and standard (neo)adjuvant chemotherapy; stage I-III.

Key finding

BEATRICE showed no iDFS or OS benefit from adding 1 year of adjuvant bevacizumab to standard chemotherapy in early TNBC. Definitively negative result in early breast.

Source: PMID 23932548

Timeline

  • Publication: 2013 Sep

Guideline citations

  • NCCN BREAST